Wedge Capital Management L L P NC Lowers Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Wedge Capital Management L L P NC decreased its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 19.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 188,785 shares of the biopharmaceutical company’s stock after selling 44,264 shares during the quarter. Wedge Capital Management L L P NC owned 0.06% of Amicus Therapeutics worth $2,016,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in FOLD. Xponance Inc. boosted its stake in shares of Amicus Therapeutics by 5.3% in the second quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 936 shares during the period. American International Group Inc. lifted its holdings in Amicus Therapeutics by 0.9% during the 4th quarter. American International Group Inc. now owns 141,249 shares of the biopharmaceutical company’s stock worth $2,004,000 after buying an additional 1,298 shares in the last quarter. Arizona State Retirement System boosted its position in Amicus Therapeutics by 2.6% in the 2nd quarter. Arizona State Retirement System now owns 62,020 shares of the biopharmaceutical company’s stock valued at $615,000 after buying an additional 1,577 shares during the period. Diversified Trust Co grew its stake in shares of Amicus Therapeutics by 3.8% in the third quarter. Diversified Trust Co now owns 74,501 shares of the biopharmaceutical company’s stock worth $796,000 after acquiring an additional 2,698 shares in the last quarter. Finally, Principal Financial Group Inc. increased its position in shares of Amicus Therapeutics by 1.1% during the second quarter. Principal Financial Group Inc. now owns 240,813 shares of the biopharmaceutical company’s stock worth $2,389,000 after acquiring an additional 2,737 shares during the period.

Insiders Place Their Bets

In other news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $10.60, for a total value of $79,500.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $9,398,532.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 22,500 shares of company stock valued at $244,875 over the last quarter. Company insiders own 2.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on FOLD. JPMorgan Chase & Co. decreased their target price on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, August 16th. StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 target price on shares of Amicus Therapeutics in a report on Friday, September 20th. Morgan Stanley lowered their price target on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Finally, Jefferies Financial Group began coverage on shares of Amicus Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $18.00 price objective for the company. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.88.

Amicus Therapeutics Trading Up 1.8 %

Shares of Amicus Therapeutics stock opened at $10.50 on Thursday. The company has a current ratio of 2.75, a quick ratio of 2.26 and a debt-to-equity ratio of 2.93. The company has a fifty day simple moving average of $11.15 and a 200-day simple moving average of $10.55. The stock has a market cap of $3.11 billion, a price-to-earnings ratio of -21.43 and a beta of 0.69. Amicus Therapeutics, Inc. has a 12-month low of $9.02 and a 12-month high of $14.57.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The company had revenue of $126.67 million during the quarter, compared to the consensus estimate of $121.21 million. During the same quarter in the prior year, the firm posted ($0.15) earnings per share. Amicus Therapeutics’s revenue for the quarter was up 34.0% on a year-over-year basis. On average, equities analysts forecast that Amicus Therapeutics, Inc. will post -0.07 EPS for the current fiscal year.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.